key: cord-345014-qp13h0un authors: Stein, Richard Albert title: The 2019 coronavirus: Learning curves, lessons, and the weakest link date: 2020-03-13 journal: Int J Clin Pract DOI: 10.1111/ijcp.13488 sha: doc_id: 345014 cord_uid: qp13h0un In the space of just six weeks, a new coronavirus, from a family that historically was not viewed as a global health concern, has become daily headline news around the globe. The 21st century marked its arrival with the emergence of three previously unknown coronaviruses. SARS-CoV (severe acute respiratory syndrome coronavirus) was recognized in November 2002 [1, 2], MERS-CoV (Middle East respiratory syndrome coronavirus) in June 2012 [3, 4], and 2019-nCoV in December 2019 [5]. Previously, human coronaviruses, known since the 1960s, were viewed as being only marginally relevant to the clinic, except for infants, the elderly, and immunocompromised individuals [1, 6, 7]. In the space of just six weeks, a new coronavirus, from a family that his torically was not viewed as a global health concern, has become daily headline news around the globe. The 21st century marked its arrival with the emergence of three previously unknown coronaviruses. SARS-CoV (severe acute respiratory syndrome coronavirus) was recognized in November 2002, 1,2 MERS-CoV (Middle East respiratory syndrome coronavirus) in June 2012, 3, 4 and 2019-nCoV in December 2019. 5 Previously, human coronaviruses, known since the 1960s, were viewed as being only marginally relevant to the clinic, except for infants, the elderly, and immunocompromised individuals. 1, 6, 7 What these, and several other recent outbreaks have in common, is how fast they circled the world. Outbreaks that centuries ago needed weeks or months to spread globally can today reach any continent within days. 8 The first, spring wave of the 1918 Spanish Flu, at a time when travel by ship was the fastest way of transportation around the world, spread through the United States, Europe, and possibly Asia over six months. 9,10 The pandemic affected over a quarter of the world's population, caused 50-100 million deaths, more than the two World Wars combined, and caused life expectancy at birth in the United States to drop by 11.8 years between 1917 and 1918. 9,11,12 In comparison, in 2002-2003 the SARS-CoV spread to 5 countries within 24 hours, 13 and in 2009 the H1N1 influenza virus spread to 30 countries within 6 weeks. 14 In the most recent of the three coronavirus outbreaks, several clusters of patients with pneumonia started to be reported on December 8, 2019 from Wuhan, China, and most of them were epidemiologically linked to the Huanan Seafood Wholesale Market. 5, [15] [16] [17] The market was closed on January 1, 2020. 5 By February 11, 2020, the virus, 2019-nCoV, was reported from >28 countries and special administrative regions, affected >43 000 people, and caused 1018 deaths. 18 The ability of the virus to spread by human-to-human transmission was confirmed. 19 A preliminary epidemiological analysis indicates that the incubation period of 2019-nCoV is similar to that of SARS, but with a wider confidence interval, and longer than the one for the 2009 H1N1 influenza strain. 20 On February 11, 2020, the disease caused by 2019-nCoV was named COVID-2019, for coronavirus disease in 2019. [21] [22] [23] Real-time information about the outbreak is available via an The prompt availability of the viral genome was critical for allowing comparisons with coronaviruses from previous outbreaks and helped make initial predictions. After the 2019-nCoV was isolated on January 7, 2020, its sequence was published on January 12, 2020. 24, 25 The virus shares >70% genetic similarity with the 2002-2003 SARS-CoV strain, 5 is most closely related to coronaviruses of bat origin, 17 its spike glycoprotein gene appears to have emerged by recombination between a bat coronavirus and a coronavirus of unknown origins, and relative synonymous codon usage bias analyses indicate that snakes may be a potential reservoir. 26 The SARS-CoV spike protein receptor binds the angiotensin-converting enzyme 2 (ACE2) on host cells, an interaction that shapes cross-species and human-to-human transmission. 27,28 ACE2 is a metallopeptidase expressed in numerous tissues, including alveolar epithelial cells and enterocytes. [29] [30] [31] [32] Sequencing indicates that the 2019-nCoV might also use ACE2 as a receptor. 33 The 2019-nCoV spike receptor-binding domain is 73%-76% similar at the genomic level to the one from the SARS-CoV from human, civet, or bat viruses. 33 with, but not ideal for binding human ACE2, suggests that the virus has acquired the ability for human-to-human transmission, but this appears to be more limited than that of the 2002-2003 SARS-CoV strain. 26 The mutation of this asparagine to threonine in 2019-nCoV was predicted to significantly increase the ability of the virus to bind the human ACE2 receptor and should be closely monitored for. 33 One of the earliest interventions during the 2019-nCoV outbreak involved quarantining an estimated 50-60 million people in multiple Chinese cities, in what appears to be the largest mass quarantine in history. 37, 38 It is still too early to visualize the impact of this initiative on the global dynamics of the outbreak, and retrospective analyses will be critical. Quarantines, even though they are controversial, come at a high cost, and have been viewed with suspicion, were historically found to delay and slow the spread of various outbreaks. [39] [40] [41] [42] [43] Quarantines are one of the non-pharmaceutical interventions, which also include personal hygiene measures, cancellation of mass gatherings and public events, school and workplace closure, and travel restrictions. [44] [45] [46] What all these interventions share is that at least during the initial stages of a new outbreak, particularly when a novel pathogen is involved and therapies are not yet available, they are one of the few options available. A lesson that flu taught us is that non-pharmaceutical interventions are at least as important as drugs or vaccines in controlling a pandemic. 47 Taiwan. 54, 55 In Italy, even though entry screening was conducted at two international airports, none of the 72 individuals, including four probable SARS cases, that were admitted for clinical evaluation, were referred to the hospitals by airport authorities. 56 Some of the limitations of screening measures, in the wake of an outbreak, include denying contact with ill individuals, taking antipyretic medication to conceal fever, 51 and its reliance on the length of the incubation period of the infectious disease. 57 About 400 new infectious diseases were identified since 1940, and new pathogens emerge at faster rates. 10,58-60 Every outbreak brings something new, provides opportunities to reap the benefits gained from past epidemics and pandemics, and provides novel lessons that will shape the framework to manage emerging infectious diseases. One aspect that all outbreaks share is their potential for rapid global dissemination through air travel. As we attempt to predict and quantitate the impact of international travel on an infectious disease outbreak and visualize the host, environmental, and microbial factors that make some outbreaks spread faster and others have higher mortality, it is worth noting that in 2013, for the first time, the annual number of passengers exceeded three billion. 8 An estimated one million people travel internationally every day, one million people travel between developing and developed countries every week, 61 and the volume of airline passengers increases annually. 62 In 2014, for the first time, the daily number of flights exceeded an annual average of 100 000. 8 It has become increasingly easy to reach any continent within 24 hours, a period that is shorter than the incubation time of most contagious diseases. 63 defined as contagious hosts that create more secondary contacts that most others in the population, will be a critical component of retrospective analyses, and there is an indication that super-spreading might already have occurred in the current outbreak. 66 An important consideration, for this and future outbreaks, is understanding the types of different non-pharmaceutical interventions, their combined benefit, and the best timing for their implementation. This is both a learning curve and a new lesson in the wake of every epidemic, most likely riddled with differences even between two nearby cities impacted by the same outbreak. However, this is also the weakest link and the one that will indisputably assume a critical role in the management of zoonotic infectious diseases, a world where, as we know by now, history keeps repeating itself. As of February 26, 2020, >82,000 COVID-19 infections and 2,798 deaths were reported. The first major outbreak in Europe, and the largest one outside of Asia, was reported in Italy, with 453 cases and 7 deaths as of February 26, 2020. In Italy, the difficulty to trace the chain of the outbreak to the first infection in the country represents a huge setback in terms of the public health interventions that could help contain the spread of the virus. The A decade after SARS: strategies for controlling emerging coronaviruses SARS and MERS: recent insights into emerging coronaviruses Infection with Middle East respiratory syndrome coronavirus Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -the latest 2019 novel coronavirus outbreak in Wuhan, China Effects of coronavirus infections in children Human coronavirus and severe acute respiratory infection in Southern Brazil Reviewing the history of pandemic influenza: understanding patterns of emergence and transmission Influenza: the mother of all pandemics Consequences of delays and imperfect implementation of isolation in epidemic control Infectious disease threats in the twenty-first century: strengthening the global response The 1918 influenza epidemic's effects on sex differentials in mortality in the United States Overview of the SARS Epidemic Institute of Medicine (US). III, Global Challenges A new coronavirus associated with human respiratory disease in China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Tracking the Wuhan coronavirus A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Epidemiological characteristics of novel coronavirus: an interim review Coronavirus updates: The illness now has a name: COVID-19. The New York Times New coronavirus disease officially named COVID-19 by the World Health Organization. National Public Radio Coronavirus latest: WHO officially names disease COVID-19. Nature World Health Organization. Emergencies preparedness, response. Pneumonia of unknown origin -China Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome Cross-species transmission of the newly identified coronavirus 2019-nCoV Reconstitution of the receptor-binding motif of the SARS coronavirus Receptor recognition and cross-species infections of SARS coronavirus ACE2 gene expression is up-regulated in the human failing heart A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS SARS vaccine development Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions Laboratory diagnosis of four recent sporadic cases of community-acquired SARS China is about to find out whether its mass quarantine worked. Bloomberg China's unprecedented quarantine of 11 million people in Wuhan is 2 weeks old. Here's what it's like in the isolated city Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings-international travel-related measures The influenza pandemic of 1918-1919 in two remote island nations: Iceland and New Zealand Modeling the impact of air, sea, and land travel restrictions supplemented by other interventions on the emergence of a new influenza pandemic virus Quarantine for pandemic influenza control at the borders of small island nations Lessons from the history of quarantine, from plague to influenza A Design of non-pharmaceutical intervention strategies for pandemic influenza outbreaks Predicting support for non-pharmaceutical interventions during infectious outbreaks: a four region analysis Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review Social measures may control pandemic flu better than drugs and vaccines Public health interventions and epidemic intensity during the 1918 influenza pandemic Fears are rising over the spread of China's deadly Wuhan virus, which has now reached the US. Here's how airports around the world are trying to stop it Entry and exit screening of airline travellers during the A(H1N1) 2009 pandemic: a retrospective evaluation Border screening for SARS in Australia: what has been learnt? Border screening for SARS Exit and entry screening practices for infectious diseases among travelers at points of entry: looking for evidence on public health impact Public health interventions and SARS spread Use of quarantine to prevent transmission of severe acute respiratory syndrome-Taiwan Border screening for SARS Effectiveness of traveller screening for emerging pathogens is shaped by epidemiology and natural history of infection Prediction and prevention of the next pandemic zoonosis Infectious diseases are spreading more rapidly than ever before, WHO warns Emerging virus diseases: can we ever expect the unexpected? Global change and human vulnerability to vector-borne diseases The use and reporting of airline passenger data for infectious disease modelling: a systematic review Infectious risks of air travel Preparing for the next pandemic Global surveillance, national surveillance, and SARS How to cite this article: Stein RA. The 2019 coronavirus: Learning curves, lessons, and the weakest link